Ar-He targeted tumor therapy technology is a minimally invasive surgical tumor treatment system (Endocare CryocareTM Surgical System, referred to as Ar-He knife) approved by the authoritative U.S. FDA in 1998 and certified by the European Union CE on behalf of the 21st Century Science and Technology Development Level. It adopts argon target cooling, helium target heating, biological sensing, timely monitoring and minimally invasive a number of U.S. computer and aerospace technology patents developed, has become the international field of low-temperature targeted therapy in the field of high-tech development of newer and newer technologies, is the successor to the radio frequency, microwave, laser, ultrasonic aggregation, ! -After radio frequency, microwave, laser, ultrasonic aggregation, ray and neutron ray, it is a new local ablation treatment method for tumor. Due to its simple operation, strong targeting, wide range of indications, timely monitoring of the target area in the treatment, small damage to the patient, and precise ablation effect, CryocareTM is one of the best means of treatment for patients with solid tumors that cannot be radically resected by surgery. Zhao Wenhua, Minimally Invasive Tumor Department, Shandong Qianfoshan Hospital, Shandong Province, China In 1993, the Americans invented the argon helium cryotherapy system by applying dozens of patented technologies in space, that is, what is commonly known as the argon helium knife. In 1998, after 5 years of clinical trials, FDA approved argon helium knife into clinical application, at the same time, the United States argon helium knife also obtained the CE certification of the European Union, began to be used for solid two Adaptation signs —malignant solid tumors: liver cancer, lung cancer, brain tumors,